X4 Pharmaceuticals (XFOR) EBT (2017 - 2025)
X4 Pharmaceuticals (XFOR) reported EBT of -$23.9 million for Q4 2025, up 39.53% on a YoY basis from -$17.1 million in Q4 2024, and up 19.84% quarter-over-quarter from -$29.8 million in Q3 2025.
X4 Pharmaceuticals (XFOR) EBT (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported EBT for 9 years, with the latest figure at -$23.9 million in Q4 2025.
- For the quarter ending Q4 2025, EBT rose 39.53% year-over-year to -$23.9 million; the trailing twelve-month figure through Dec 2025 stood at -$79.2 million (down 113.13% YoY), and the FY2025 full-year result was -$79.2 million, down 113.13% from the prior year.
- EBT for Q4 2025 stood at -$23.9 million, up from -$29.8 million in the prior quarter.
- The five-year high for EBT was $90.9 million in Q2 2024, with the low at -$55.7 million in Q2 2023.
- Historically, EBT has averaged -$20.0 million across 5 years, with a median of -$22.9 million in 2022.
- The largest YoY upside for EBT was 263.12% in 2024 against a maximum downside of 1509.52% in 2024.
- X4 Pharmaceuticals' EBT stood at -$30.2 million in 2021, then advanced by 3.69% to -$29.1 million in 2022, then surged by 34.35% to -$19.1 million in 2023, then tumbled by 107.17% to -$39.6 million in 2024, then surged by 39.53% to -$23.9 million in 2025.
- The last three EBT figures came in at -$23.9 million (Q4 2025), -$29.8 million (Q3 2025), and -$25.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | -23.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.93 Mn |
| Sep 30, 2025 | -29.85 Mn |
| Jun 30, 2025 | -25.70 Mn |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | -39.56 Mn |
| Sep 30, 2024 | -36.68 Mn |
| Jun 30, 2024 | 90.85 Mn |
| Mar 31, 2024 | -51.75 Mn |
| Dec 31, 2023 | -19.10 Mn |
| Sep 30, 2023 | -2.28 Mn |
| Jun 30, 2023 | -55.70 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.09 Mn |
| Sep 30, 2022 | -21.60 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.94 Mn |
| Dec 31, 2021 | -30.20 Mn |
| Sep 30, 2021 | -20.17 Mn |
| Jun 30, 2021 | -19.63 Mn |
| Mar 31, 2021 | -18.67 Mn |